• PDF / 169,715 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 2 Downloads / 163 Views

DOWNLOAD

REPORT

---

1 S

Bronchial anastomotic dehiscence: 3 case reports A retrospective, large, multicenter, observational cohort study involving 226 patients, who had lung transplantation for pulmonary fibrosis between January 2012 and December 2017, 3 patients (2 men and 1 woman) aged 62–68 years were described, who developed bronchial anastomotic dehiscence during treatment with pirfenidone and nintedanib as an anti-fibrotic therapy. The patients had undergone bilateral lung transplantation for pulmonary fibrosis. During the transplantation, the patients received treatment with pirfenidone (2 patients) and nintedanib (1 patient) as an anti-fibrotic therapy [routes and dosages not stated]. Following 17–29 days, the patients developed bronchial anastomotic dehiscence. Microbiology testing showed various infections involving Burkholderia cepacia, Aspergillus species, Penicillium species, Pseudomonas, Enterobacter, Penicillium species or Staphylococcus aureus. The patients required prolonged hospitalisation due to bronchial anastomotic dehiscence. Afterwards, one of the patient underwent stent placement, but died due to Burkholderia cepacia sepsis and in the remaining two patients the dehiscence resolved without any bronchial intervention. Mackintosh JA, et al. Risk of anastomotic dehiscence in patients with pulmonary fibrosis transplanted while receiving anti-fibrotics: Experience of the Australian Lung Transplant Collaborative. Journal of Heart and Lung Transplantation 38: 553-559, No. 5, May 2019. Available from: URL: http://doi.org/10.1016/ 803519658 j.healun.2019.02.005

0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Dec 2020 No. 1833